LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Inicio・Lista de Acciones・Incyte Corp

Incyte Corp

Cerrado

SectorSanidad

102.35 1

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

100.15

Máximo

106.2

Métricas clave
By Trading Economics
Ingresos	4.1M 303M
Ventas	-234M 1.3B
P/B Media del Sector	13.501 49.888
BPA	1.81
Margen de beneficios	23.834
Empleados	2,844
EBITDA	-47M 368M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+7.47% upside

Dividendos
By Dow Jones
Próximas Ganancias	28 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	49M 19B
Apertura anterior	101.35
Cierre anterior	102.35

Noticias sobre sentimiento de mercado

By Acuity

66%

34%

289 / 344 Clasificación en Healthcare

Incyte Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

5 jun 2026, 19:20 UTC

Principales Movimientos del Mercado

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5 jun 2026, 21:27 UTC

Ganancias

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 jun 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

5 jun 2026, 20:20 UTC

Adquisiciones, fusiones, absorciones

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 jun 2026, 20:19 UTC

Adquisiciones, fusiones, absorciones

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 jun 2026, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

5 jun 2026, 19:26 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 jun 2026, 19:26 UTC

Charlas de Mercado

Hog Futures Tumble to Close Week -- Market Talk

5 jun 2026, 19:10 UTC

Charlas de Mercado

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 jun 2026, 19:03 UTC

Charlas de Mercado

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 jun 2026, 18:59 UTC

Charlas de Mercado

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 jun 2026, 18:47 UTC

Charlas de Mercado

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 jun 2026, 18:34 UTC

Charlas de Mercado

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 jun 2026, 18:33 UTC

Adquisiciones, fusiones, absorciones

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 jun 2026, 17:50 UTC

Ganancias

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 jun 2026, 17:27 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 jun 2026, 16:48 UTC

Adquisiciones, fusiones, absorciones

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 jun 2026, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

5 jun 2026, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

5 jun 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

5 jun 2026, 15:44 UTC

Adquisiciones, fusiones, absorciones

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 jun 2026, 15:26 UTC

Charlas de Mercado

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 jun 2026, 15:25 UTC

Ganancias

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 jun 2026, 15:16 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 jun 2026, 15:16 UTC

Charlas de Mercado

Zcash Tumbles After Exploit Found -- Market Talk

5 jun 2026, 15:09 UTC

Charlas de Mercado

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5 jun 2026, 15:07 UTC

Charlas de Mercado

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5 jun 2026, 15:05 UTC

Charlas de Mercado

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Comparación entre iguales

Cambio de precio

Incyte Corp previsión

Precio Objetivo

By TipRanks

7.47% repunte

Estimación a 12 Meses

Media 108.8 USD 7.47%

Máximo 135 USD

Mínimo 75 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Incyte Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

18 ratings

Comprar

Mantener

Vender

De acuerdo con 18 analistas que ofrecen calificaciones bursátiles a para Incyte Corp Dist en los últimos 3 meses.

Sentimiento

By Acuity

289 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation